A Common Nonsynonymous Single Nucleotide Polymorphism in the SLC30A8 Gene Determines ZnT8 Autoantibody Specificity in Type 1 Diabetes

Janet M. Wenzlau,1 Yu Liu,2 Liping Yu,1 Ong Moua,1 Kimberly T. Fowler,1 Sampathkumar Rangasamy,1 Jay Walters,1 George S. Eisenbarth,1 Howard W. Davidson,1 and John C. Hutton1

OBJECTIVE—Zinc transporter eight (SLC30A8) is a major target of autoimmunity in human type 1A diabetes and is implicated in type 2 diabetes in genome-wide association studies. The type 2 diabetes nonsynonymous single nucleotide polymorphism (SNP) affecting aa325 lies within the region of highest ZnT8 autoantibody (ZnT8A) binding, prompting an investigation of its relationship to type 1 diabetes.

RESEARCH DESIGN AND METHODS—ZnT8A radioimmuno-precipitation assays were performed in 421 new-onset type 1 diabetic Caucasians using COOH-terminal constructs incorporating the known human aa325 variants (Trp, Arg, and Gln). Genotypes were determined by PCR-based SNP analysis.

RESULTS—Sera from 224 subjects (53%) were reactive to Arg325 probes, from 185 (44%) to Trp325 probes, and from 142 (34%) to Gln325 probes. Sixty subjects reacted only with Arg325 constructs, 31 with Trp325 only, and 1 with Gln325 only. The restriction to either Arg325 or Trp325 corresponded with inheritance of the respective C- or T-alleles. A strong gene dosage effect was also evident because both Arg- and Trp-restricted ZnT8As were less prevalent in heterozygous than homozygous individuals. The SLC30A8 SNP allele frequency (75% C and 25% T) varied little with age of type 1 diabetes onset or the presence of other autoantibodies.

CONCLUSIONS—The finding that diabetes autoimmunity can be defined by a single polymorphic residue has not previously been documented. It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes. It has implications for antigen-based therapeutic interventions because the response to ZnT8 administration could be protective or immunogenic depending on an individual's genotype. Diabetes 57:2693–2697, 2008

From the 1Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado; and the 2Department of Endocrinology, Nanjing Medical University, First Affiliated Hospital, Nanjing, China. Corresponding author: John C. Hutton, john.hutton@uchsc.edu.

RESEARCH DESIGN AND METHODS—ZnT8A radioimmuno-precipitation assays were performed in 421 new-onset type 1 diabetic Caucasians using COOH-terminal constructs incorporating the known human aa325 variants (Trp, Arg, and Gln). Genotypes were determined by PCR-based SNP analysis.

RESULTS—Sera from 224 subjects (53%) were reactive to Arg325 probes, from 185 (44%) to Trp325 probes, and from 142 (34%) to Gln325 probes. Sixty subjects reacted only with Arg325 constructs, 31 with Trp325 only, and 1 with Gln325 only. The restriction to either Arg325 or Trp325 corresponded with inheritance of the respective C- or T-alleles. A strong gene dosage effect was also evident because both Arg- and Trp-restricted ZnT8As were less prevalent in heterozygous than homozygous individuals. The SLC30A8 SNP allele frequency (75% C and 25% T) varied little with age of type 1 diabetes onset or the presence of other autoantibodies.

CONCLUSIONS—The finding that diabetes autoimmunity can be defined by a single polymorphic residue has not previously been documented. It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes. It has implications for antigen-based therapeutic interventions because the response to ZnT8 administration could be protective or immunogenic depending on an individual's genotype. Diabetes 57:2693–2697, 2008

Human type 1A diabetes results from autoimmune destruction of pancreatic β-cells targeted at a restricted number of autoantigens, many of which show high β-cell specificity of expression (1). Susceptibility to the disease is associated with multiple genetic loci, most prominently HLA alleles encoding particular major histocompatibility complex class II glycoproteins (2).

ZnT8 is a newly discovered target of type 1 diabetes autoimmunity (3) localized to the insulin granule of the pancreatic β-cell. It is encoded by SLC30A8, one of nine human genes for multispanning transmembrane proteins facilitating Zn2+ efflux from the cell and sequestration into intracellular compartments (4,5). Recent genome-wide association studies demonstrate association of ZnT8 gene polymorphisms with human type 2 diabetes (6–9), notably a nonsynonymous SNP encoding either Arg or Trp at aa325. The major, Arg325-encoding C-allele confers a minor risk (odds ratio 1.07–1.18) of disease. In nondiabetic subjects with a family history of type 2 diabetes, the C-allele was associated with increased insulin sensitivity (10), increased circulating proinsulin-to-insulin ratio (11), and decreased insulin responses in intravenous glucose tolerance tests (12), indicating a dominant effect on insulin secretion, β-cell mass, or both.

We report here that the type 1 diabetes autoimmune response to ZnT8 is focused on a few key epitopes, two of which are defined by the polymorphic aa325 residue. To our knowledge, this is the first reported instance where a polymorphic variant determines the specificity of the autoimmune response. It indicates that the autoreactive B-lymphocyte repertoire is restricted to a few ZnT8 epitopes and is truly self-reactive as opposed to arising as a bystander response to a foreign antigen.

RESEARCH DESIGN AND METHODS—ZnT8A radioimmuno-precipitation assays were performed in 421 new-onset type 1 diabetic Caucasians using COOH-terminal constructs incorporating the known human aa325 variants (Trp, Arg, and Gln). Genotypes were determined by PCR-based SNP analysis.

RESULTS—Sera from 224 subjects (53%) were reactive to Arg325 probes, from 185 (44%) to Trp325 probes, and from 142 (34%) to Gln325 probes. Sixty subjects reacted only with Arg325 constructs, 31 with Trp325 only, and 1 with Gln325 only. The restriction to either Arg325 or Trp325 corresponded with inheritance of the respective C- or T-alleles. A strong gene dosage effect was also evident because both Arg- and Trp-restricted ZnT8As were less prevalent in heterozygous than homozygous individuals. The SLC30A8 SNP allele frequency (75% C and 25% T) varied little with age of type 1 diabetes onset or the presence of other autoantibodies.

CONCLUSIONS—The finding that diabetes autoimmunity can be defined by a single polymorphic residue has not previously been documented. It argues against ZnT8 autoimmunity arising from molecular mimicry and suggests a mechanistic link between the two major forms of diabetes. It has implications for antigen-based therapeutic interventions because the response to ZnT8 administration could be protective or immunogenic depending on an individual’s genotype. Diabetes 57:2693–2697, 2008

From the 1Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, Colorado; and the 2Department of Endocrinology, Nanjing Medical University, First Affiliated Hospital, Nanjing, China. Corresponding author: John C. Hutton, john.hutton@uchsc.edu.

© 2008 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
ZnT8 autoantibody (ZnT8A) radioimmunoprecipitation assays used 35S-Met–labeled in vitro transcribed and translated probes of hZnT8 COOH-terminal cytosolic segments (aa268–369) encoding the aa325 codon variants CCG (Arg), TCG (Trp), and CAG (Gln) (supplementary Fig. 1, available in an online appendix at http://dx.doi.org/10.2337/db08-0522). Assay procedures have previously been described (3,14). ZnT8A assay data were normalized to a panreactive positive control sera (1:50) generated in rabbits to a glutathione-S-transferase/C-term Trp325 fusion protein and 16 human control sera in the same assay (3). Recombinant NUS-ZnT8 fusion proteins were generated in pET43.1 (EMD Biosciences, San Diego, CA), expressed in BL-21(DE3) Escherichia coli, and purified by Ni-NTA agarose chromatography (Qiagen, Hilden, Germany). Synthetic 20-mer peptides were from Sigma Genosys (Woodlands, TX). For preabsorption, sera (5 µl) were preincubated with 10 µg protein or peptide in 40 µl PBS at 20°C for 2 h before addition of the radiolabeled antigen to initiate the assay. Results are expressed as means ± SD; statistical analyses were performed with the Prism 4.0 software package (www.graphpad.com).

RESULTS
The present study was initiated to resolve a paradoxical finding that two constructs bearing the COOH-terminal antigenic region of ZnT8 with or without the NH2-terminus (supplementary Fig. 1) were recognized in a differential fashion by subsets of type 1 diabetes new-onset sera (3). The constructs were derived from different cDNAs and subsequently shown to encode the Arg (C-probe) or Trp (NC-probe) variants of aa325. To further explore this phenomenon, assays were performed in sera from newly diagnosed type 1 diabetic patients using COOH-terminal ZnT8 probes bearing Arg, Trp, or Gln at aa325; 259 of 421 individuals (61.5%) reacted to at least one probe, with the highest response recorded in reaction to the Arg variant (53.2%) followed by Trp (43.9%) and Gln (33.7%) (*P* < 0.0001, χ²). Analysis of the overlap in responses (Fig. 1A) shows that some individuals react to the Arg or Trp probes alone and very rarely to Gln alone; 29.7% of individuals reacted to all three probes.

A comparison of the levels of autoantibody reactivity to the Arg and Gln probes (Fig. 1B) showed that the majority

FIG. 1. Relationship between autoantibody responses to Arg, Trp, and Gln constructs. A: Venn diagram illustrating the overlap of antibody detection with each of the polymorphic probes in the entire population (n = 421) in the study. The prevalence in each sector is expressed as a percentage of the population total. B–D: Assays were performed on the same set of 117 new-onset type 1 diabetic individuals and stratified as indicated; the numbers in each sector are shown in parentheses. The cutoff for positive responses was set at 0.05 (vertical and horizontal lines). Responses judged to be equivalent are set by the boundaries indicated by the angled lines, which correspond to a 3-SD excursion from the diagonal, assuming an intrassay coefficient of variation of 12.5% for each sample. Data are expressed as the immunoprecipitation index (sample-control)/(positive sample [BUNE]-control).
of individuals either reacted equivalently to the probes (falling within the bounds of the diagonal of the x-y plot ± 3 SD) or responded to the Arg probe alone. Trp and Gln reactivities (Fig. 1C) were similarly separated. Of the 34 patients who reacted equivalently to Arg and Trp probes (within the bounds of the diagonal ± 3 SD of Fig. 1D), 29 (85.3%) had an equivalent response as determined by the Gln probe. This indicated that for these individuals, the aa at position 325 was not a determinant of autoantibody reactivity. A series of preabsorption experiments was therefore performed using peptides and recombinant proteins as competing ligands (Fig. 2). Selected type 1 diabetic sera that reacted with the Arg probe alone were blocked by recombinant NUS-C-term Arg325 protein but not by NUS-C-term Trp325 or NUS-C-term Gln325. Similarly, Trp-only responses were blocked by NUS-C-term Trp325 but not NUS-C-term Arg325 or NUS-C-term Gln325. Sera that reacted equivalently to Arg, Trp, and Gln probes were blocked by any of the NUS-C-term ZnT8 recombinants. Overlapping 20-mer peptides spanning the ZnT8 C-terminal domain 259–369 did not compete for reactivity, suggesting that the epitopes were conformational rather than linear. Overall, these results suggest that ZnT8A reactivity could be accounted for by three classes of conformational epitopes: one for which Arg325 was an essential determinant, a second Trp325 restricted, and a third not affected by aa325.

The relationship between ZnT8 autoantibody reactivity and genetic variation at the SLC30A8 locus was examined using the SNP (rs13266634) encoding the Arg/Trp325 variant and two adjacent noncoding SNPs identified in a type 2 diabetes genome-wide association study (6), rs2466295, located 259 bp distally in the 3′ UTR, and rs6496795, located 19635 bp proximally in intron 2. The minor allele frequency (MAF) for rs13266634 in our type 1 diabetic population of 0.266 (n = 351) approximated the reference frequency of 0.256 (n = 168) for Europeans in the NLM SNP database (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs = 13266634). The distribution of genotypes (55.3% CC, 36.2% CT, and 8.5% TT) was consistent with Hardy-Weinberg distribution (53.9, 39.0, and 7.1, respectively). Similar correlations were observed for the MAF for rs6496795 (0.285 vs. 0.220 in our study vs. the NLM SNP database, respectively) and rs2466295 (0.361 vs. 0.407).

The specificity of the ZnT8A response reflected the rs13266634 genotype (Table 1), with little or no association observed with the adjacent NUS-C-term ZnT8A fusion protein for 2 h at room temperature before addition of the designated labeled probe and then processed by the usual procedure.

![Diagram](image)

**FIG. 2. Preabsorption of autoantibodies with recombinant proteins.** Single sera samples were selected from hArg-restricted sera, hCTrp-restricted sera, or samples that react equivalently with hCGln, hCArg, and hCTrp probes. Samples were preincubated without (-) or with 10 μg of the indicated affinity-purified NUS-C-term ZnT8 fusion protein for 2 h at room temperature before addition of the designated labeled probe and then processed by the usual procedure.

**Data are n (%) unless otherwise indicated. Serum from each type 1 diabetic subject was assayed with ZnT8 C-term probes incorporating Gln, Arg, or Trp at aa325 or insulin, GAD65, or IA-2. P values were calculated by a 3 × 2 Fisher exact test comparing the seropositivity (index >0.02) to the number of subjects, stratified by rs13266634 genotypes. +, positive.

**Table 1**

| rs13266634 genotype | CC | CT | TT | P     |
|---------------------|----|----|----|-------|
| n                   | 351| 194| 127| 30    |
| Any probe+          | 220(62.7)| 128(66.0)| 70(55.1)| 22(73.3)| 0.07   |
| All probes+         | 107(30.5)| 63(32.5)| 37(29.1)| 7(23.3)| 0.55   |
| Gln probe           | 125(35.6)| 75(38.7)| 42(33.1)| 8(26.7)| 0.33   |
| Arg probe           | 196(55.8)| 124(63.9)| 63(49.6)| 9(30.0)| 0.0005 |
| Trp probe           | 154(43.9)| 71(36.6)| 61(48.0)| 22(73.3)| 0.0004 |
| Gln only            | 1(0.3)| 1(0.5)| 0(0.0)| 0(0.0)| 0.67   |
| Arg only            | 52(14.8)| 45(23.2)| 7(5.5)| 0(0.0)| <0.0001|
| Trp only            | 18(5.1)| 1(0.5)| 5(3.9)| 12(40.0)| <0.0001|
| Insulin             | 171(48.7)| 89(45.9)| 68(53.5)| 14(46.7)| 0.39   |
| GAD65               | 204(58.1)| 108(55.7)| 82(64.6)| 14(46.7)| 0.12   |
| IA-2                | 254(72.4)| 144(74.2)| 88(69.3)| 22(73.3)| 0.62   |

The prevalence of ZnT8A measured with Gln325, Arg325, and Trp325 COOH-terminal probes increased with increasing age of onset, reached a plateau at 8–16 years, and then
DISCUSSION

The COOH-terminal domain of ZnT8 to which type 1 diabetes autoantibodies bind (3) incorporates a conserved protein fold found in the large family of cation diffusion facilitator efflux carriers and has orthologs in all cellular organisms (15). Autoantibodies to ZnT8 in human type 1 diabetic patients, however, show little characteristic changes in prevalence relative to age of onset of disease, insulin autoantibody prevalence being highest in younger onset patients, IA-2 antibody tending to be higher in adolescents than children, and GAD antibody showing little variation (Fig. 3B).

The autoantibody responses to the ZnT8 Arg- and Trp-restricted isoepitopes segregated with the alleles encoding the respective variant amino acids, indicating that humoral type 1 diabetes autoimmunity to ZnT8 is directed against self and not nonself epitope determinants. This argues against the molecular mimicry hypothesis that suggests that autoimmunity is triggered by an initial immune response to an infectious agent that in turn triggers reactivity to self because of sequence homology between the pathological agent and a self protein (16–20). Our results favor the idea that ZnT8 autoreactivity arises because of a defect in induction of self-tolerance, since the mimicry model would more likely favor one isoepitope over another, which in turn would be manifest as genetic dissociation of the encoding allele with the disease. The MAF of the rs13266634 SNP in the type 1 diabetic population under study was, however, similar to reference populations, and no association of the SNP was seen with age of diabetes onset or the prevalence of antibodies to ZnT8 or other diabetes autoantigens. We cannot, however, preclude a role for molecular mimicry in T-cell recognition of antigenic peptides or in antigen presentation to CD4+ T-cells because antigen/antibody binding can directly influence the peptides presented from the antigen by virtue of altering intracellular proteolytic processing (21,22).
While the rs13266634 genotype or ZnT8 isoepitope specificities may not markedly affect type 1 diabetes susceptibility or age of onset, their measurement will be important in a number of clinical settings. Since ZnT8 autoantibodies provide an independent marker of disease susceptibility in pre-diabetic individuals (3), measurements based on a single aa325 probe would underestimate ZnT8 autoimmunity by as much as 20% given the differences in rs13266634 SNP allele frequency (12) and thus affect inclusion in clinical trials. Given its high tissue specificity, ZnT8 is an attractive candidate as a component of a DNA- or peptide-based vaccine (23,24) to prevent or retard the onset of type 1 diabetes. In this context, it is likely to be important to match the molecular form of the antigen to the recipient because mismatching the isoepitope might lead to immunization and acceleration of disease rather than induction of tolerance.

ACKNOWLEDGMENTS

This study was supported by the Childhood Diabetes Foundation in Denver, the University of Colorado Health Sciences Diabetes and Endocrinology Research Center (National Institutes of Health [NIH] P30 DK57516), NIH RO1 DK052068, and a Juvenile Diabetes Research Foundation Center grant. Y.L. and R.S. were recipients of American Diabetes Association (ADA) mentor-based postdoctoral awards, and K.F. received an ADA mentor-based minority postdoctoral award. We thanks Marian Rewers and Pam Fain for helpful discussion; Sunanda Babu, Randall Wong, and Erin Stewart for technical support; and the patients and families for their participation in this study.

REFERENCES

1. Lieberman SM, DiLorenzo TP: A comprehensive guide to antibody and T-cell responses in type 1 diabetes. Tissue Antigens 65:359–377, 2003
2. Alarcon-Riquelme ME: Recent advances in the genetics of autoimmune diseases. Ann N Y Acad Sci 1110:1–9, 2007
3. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb PA, Rewers M, Eisenbarth GS, Jensen J, Davidson HW, Hutton JC: The cation efflux transporter ZnT8 (SCL30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 104:17040–17045, 2007
4. Palminteri RD, Huang L: Efflux and compartmentalization of zinc by members of the SLC30 family of solute carriers. Pflugers Arch 447:744–751, 2004
5. Chimenti F, Devergnas S, Favier A, Seve M: Identification and cloning of a β-cell-specific zinc transporter, ZnT-8, localized into insulin secretory granules. Diabetes 53:2330–2337, 2004
6. Sladek R, Rocheleau G, Rung J, Dina C, Shen L, Serre D, Boutin P, Vincent M, Iqbal S, Nocon N, Chagnon YC, Ovesen L, Thibault P, Cooper R, Takeno M, Haffner S, Dina C, Boeheim C, Ferrell RE, Clark LC, Jackson AU, Dina C, Mychaleckyj JC, Frayling TM, Green A, Utermann G, Langenbach R, Fournier C, Cupples LA, Speliotes EK, Bergman RN, Hixson JE, Zhang Q, Langefeld CD, Loos RJ, Almgren P, Tuomilehto J, Hattersley AT, Monda KL, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard JB, Hattersley AT, Haffner SM, Somaert E, Hixson J, Pritchard J

J.M. WENZLAU AND ASSOCIATES

DIABETES, VOL. 57, OCTOBER 2008 2697

2697